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Methylation-mediated silencing of the tumour suppressor CADM1 has been functionally linked to lung
cancer development. We aimed to determine whether CADM1 promoter methylation is a candidate
early detection marker for lung cancer. To this end frozen tissue samples of 36 non-small cell lung can-
cers, 26 corresponding tumour distant normal tissue samples as well as 6 samples of normal lung from
non-lung cancer patients were tested for DNA methylation at three different regions within the CADM1
promoter (M1, M5 and M9) using methylation speciﬁc PCR followed by methylation speciﬁc reverse line
blot analysis.
Sixty-four percentage of tumour samples tested positive at the M1 region, 47% at M5 and 74% at the M9
region, compared with 65% (M1), 23% (M5) and 46% (M9) of paired normal tissue samples. Methylation
of each of these promoter regions was also detected in the majority of non-lung cancer control samples.
Dense methylation, deﬁned as methylation at ≥2 promoter regions, was detected in 66% of tumour sam-
ples compared with 38% of paired normal tissues and 67% of non-lung cancer control samples. Within
the small subgroup of female patients dense methylation was found in all tumour samples but only 22%
of paired normal samples. Neither methylation of individual sites nor dense methylation was correlated
with disease free survival. In conclusion, CADM1 promoter methylation is a frequent event in NSCLC as
well as normal lung, both of lung cancer and non-lung cancer patients. Hence, CADM1 methylation anal-
ysis is unlikely to have diagnostic value for the early detection of lung cancer in an unselected population.
However, a diagnostic value for selected subjects, such as females, cannot be excluded.. Introduction
Lung cancer claims more lives than any other malignancy. Two
ain categories are distinguished: small cell lung cancer (SCLC)
nd non-small cell lung cancer (NSCLC). The latter, an umbrella
erm for a number of histological subtypes that comprise about
0% of lung cancers, can be cured by surgery in its earlier stages.
owever, this disease often becomes symptomatic only after the
umour has metastasised. Efforts to ﬁnd screening tests that enable
arlydiagnosis,whencurative treatment is still anoption, shouldbe
ursued. Malignant transformation is caused by a stepwise accu-
ulation of molecular changes. Theoretically, detection of these
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changes by sensitive nucleic acid ampliﬁcation assays that are
available nowadays could serve as a molecular marker for pre-
symptomatic lung cancer detection, e.g. by sputum analysis of risk
groups. Hypermethylation of tumour suppressor gene promoter
regions has generated attention since this is a frequent event in
the onset of many cancers [1,2]. Different methods to determine
DNA methylation have been developed [3]. Of these, methylation
speciﬁc PCR (MSP) is one of the most sensitive methods and con-
sequently well suited to detect low target frequencies of tumour
DNA in sputum samples.
Support for a functional involvement of methylation events
in lung cancer development has come from a recent study of
Damiani et al., who demonstrated that transformation of immor-
talized bronchial epithelial cells upon exposure to carcinogens
was causally related to an increase of DNA Methyl Transferase 1
(DNMT1) protein and concomitant de novo methylation of tumour
suppressor genes [4]. Indeed, a large number of genes has been
found to be methylated in lung cancer, of which p16, CDH13
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nd RASSF1A are amongst the most commonly methylated genes
eing described in multiple studies [5]. Analyses on sputum sam-
les revealed that a population with increased risk of lung cancer
ight be discerned using methylation markers [6–11]. One of the
romising methylation marker panels described for sputum con-
ists of APC, p16, 3OST2 and RASSF1A [11]. However, combinations
f markers with better sensitivity and speciﬁcity than those that
ave been studied so far are required to allow implementation in
creening tests [5]. Thus, there is a need for additional markers in
ung cancer that can complement currently established panels to
ncrease their efﬁcacy.
One candidate marker is methylation of the CADM1 gene.
ADM1 (cell adhesion molecule 1, originally called TSLC1 for
umour suppressor in lung cancer 1, and also referred to as
GSF4) is located in a region of chromosome 11q, which is com-
only affected by deletions in all types of lung cancer [12]. It
ncodes a transmembrane protein of the immunoglobulin super-
amily involved in cell–cell interactions between epithelial cells.
he CADM1 gene has been shown by functional complementation
tudies to inhibit tumourigenesis of lung- and cervical cancer cell
ines [13,14]. Reduced expression and/or promoter methylation of
ADM1 has been found in carcinoma of the lung, cervix, nasophar-
nx, oesophagus and breast [14–18]. The gene is silenced in most
ases through methylation of its promoter, either or not in combi-
ation with allelic loss [15,18]. In a series of 48 NSCLCs examined
sing methylation-speciﬁc single strand conformation polymor-
hism (MS-SSCP) and bisulﬁte sequencing, 21 tumours showed
ADM1promoter hypermethylation,whereas no abnormalmethy-
ation in the adjacent normal lung tissue could be detected [15].
ADM1 methylation was more frequently detected in high-grade
ung tumours [14,15] and also found to be associated with tobacco
moking and poor prognosis [19]. A recent study investigated
ADM1 as part of a panel of 27 methylation markers in NSCLC
sing semi-quantitative real-time ms-PCR (methylight). Although
ADM1 was more frequently methylated in tumour tissue than in
ormal tissue (18% vs 4%, respectively), it was not included in the
anel of 8 markers that the authors deemed most relevant because
ny added sensitivity did not outweigh the decrease in speciﬁcity
20]. Although CADM1 has proven tumour suppressive activity in
lung cancer cell line [13], and expression in lung cancers is often
educed [21,22], the reported frequencies of promoter methylation
f this gene are highly variable amongst different studies. There-
ore, noﬁrmconclusions canbedrawnyet about thepotential value
f CADM1 as biomarker for early lung cancer detection. For this a
ore comprehensive analysis is warranted.
Towards this aim we examined methylation of three CADM1
romoter regions in lung cancer tissue specimens and adjacent
ormal lung tissue samples, as well as normal lung tissue of non-
ung cancer patients using methylation speciﬁc PCR (MSP) and a
ethylation speciﬁc reverse line blot hybridisation read-out for
CR products [23]. Previous application of this methodology to
ervical carcinomas and precursor lesions, revealed an associa-
ion between methylation at ≥2 of the CADM1 promoter regions
i.e. dense methylation) and both reduced CADM1 expression and
ncreased severity of the lesion [23].
. Materials and methods
.1. Tissue samples
Tissue samples from 36 patients who had surgery for NSCLC
etween July 1987 and September 2004 as well as lung samples
rom 6 patients who underwent surgery for lung diseases other
han primary lung cancer were obtained from the lung tissue bank
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(Table 1). Specimens had been collected within an hour after sur-
gical resection and tissue of the tumour had been snap-frozen and
stored in liquid nitrogen until use. For 26 patients normal lung tis-
sue taken from the surgical specimen at maximum distance from
the tumour had been collected and snap-frozen as well. Normal
lung tissue samples from non-lung cancer controls were obtained
from patients undergoing surgery for lesions that turned out to
be pulmonary metastases of colorectal carcinoma (n=3) or non-
malignant disease (ﬁbrous scar tissue n=3). Diagnosis of the lesion
was obtained from the pathology report. A board certiﬁed patholo-
gist conﬁrmed the histology of the frozen material. Data on staging
and follow-up were obtained from patient ﬁles. This study fol-
lowed the ethical guidelines of the Internal Review Board of the
VU University Medical Center.
2.2. Laboratory procedures
DNA extracted from frozen tissue was subjected to bisulﬁte
modiﬁcation using the EZ DNA methylation kitTM (Zymo Research,
Orange, CA, USA). 500ng of DNA was modiﬁed and 25ng of mod-
iﬁed DNA was used for MSP. Laboratory procedures and MSP
primers and probes for three regions in the CADM1 promoter
(indicated as M1, M5 and M9, respectively) were as described
previously [23]. In short, PCR mixtures contained 25ng modiﬁed
DNA, 0.5M primers, each dNTP at 200M, FastStart Taq PCR
buffer (Roche Diagnostics), 1.5mM MgCl2, and 1.25U FastStart Taq
DNApolymerase (Roche Diagnostics). All U-targeted primers were
speciﬁc for unmethylated DNA, while M-targeted primers only
detected methylated DNA. Antisense primers were biotinylated for
reverse line blot (RLB) detection, in which denatured PCR-products
were hybridised to oligoprobes speciﬁc for unmethylated- and
methylated-DNA, respectively. In each run H2O, unmodiﬁed DNA
and unmethylated DNA (primary keratinocytes) were included as
negative controls and DNA isolated from the cervical cancer cell
line SiHa was included as a positive control. Analytical sensitiv-
ity of each MSP–RLB assay, as determined on a dilution series of
methylated DNA in unmethylated DNA, was 1% for M1, 5% for M5
and 0.5% for M9 [23].
2.3. Statistics
Proportions of methylated sites in tumour and tumour-distant
normal samples of NSCLC patientswere compared using theMcNe-
mar exact test and the relation of ‘dense methylation’ (i.e. MSP
positivity at ≥2 sites) with clinical characteristics was analysed
using theFisherexact test. Thepresenceof a relationbetweendense
methylation in tumour samples and different patient characteris-
tics was tested using stepwise binary logistic regression analysis
with forward selection. Relation between clinical characteristics
of NSCLC patients, dense methylation or methylation of individual
sites and disease free survival was analysed using Kaplan–Meier
survival analysis with a log rank test. A p-value of ≤0.05 was con-
sidered statistically signiﬁcant.
3. Results
Patient characteristics according to histology are summarized
in Table 1. Eleven patients had tumours with adenocarcinoma
features; adenocarcinoma (AC; n=8), adenosquamous carcinoma
(ASC; n=2) and bronchioloalveolar carcinoma (BAC; n=1). Other
histological subtypes were squamous cell carcinoma (SCC; n=19);
large cell carcinoma (LCC; n=4); mucoepidermoid carcinoma
(MEC; n=1) and carcinoid tumour (n=1). Methylation results of
individual samples are shown in Table 2.
Sixty-four percentage of tumour samples (23/36) showed
CADM1 promoter methylation at the M1 site, 47% (17/36) at the
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Table 1
Patient characteristics according to histology.
AC n=11 SCC n=19 LC-other n=6 Non-LC n=6
Age 60±11 69.6±7.9 59.2±21.6 67.0±7.7
Male 5 (45) 14 (74) 5 (83) 5 (83)
Follow-up time (years) 4.2±3.1 3.9±4.5 1.3±1.9 1.3±1.3
Disease free survival (years)a 5.0±1.2 9.9±2.2 1.9±1.0
Recurrence 6 (55) 6 (32) 3 (50)
D . AC: t
c ma, L
M
l
a
[
lata presented as mean± standard deviation or n (%) unless otherwise indicated
arcinoma (n=2), bronchioloalveolar carcinoma (n=1)), SCC: squamous cell carcino
a Mean± standard error.
5 site and 74% (26/35) at the M9 site. Dense promoter methy-
ation (deﬁned as methylation of 2 sites or more, and previously
ssociated with reduction of CADM1 expression in cervical lesions
23]) was present in 66% (23/35) of tumour samples. Dense methy-
ation was signiﬁcantly more frequent in female patients’ tumour
Table 2
Summary of methylation results on tumour samples, adjace
Black box: methylated; grey box: unmethylated, AC: aden
bronchioloalveolar carcinoma, SCC: squamous cell carcinom
carcinoma.
aPulmonary metastasis.
bNon-malignant.
ND: not done because of insufﬁcient material available.umours with adenocarcinoma features (adenocarcinoma (n=8), adenosquamous
C-other: lung cancer-other: i.e. LCC (n−4), MEC (n=1) and carcinoid (n=1).
specimens (6AC, 5 SCC and 1 carcinoid); all (12/12) specimens of
female patients revealed dense methylation vs 46% (11/24) of the
male patients’ tumours (p=0.002) (Table 3).
Normal lung tissue taken at a maximum distance from the
tumour was available for 26 of 36 NSCLC patients. The M1 site was
nt normal samples and controls.
ocarcinoma, ASC: adenosquamous carcinoma, BAC:
a, LCC: large cell carcinoma, MEC: mucoepidermoid
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Table 3
Percentage methylation per site in tissue samples from NSCLC patients.
Total M1 M5 M9 ≥2 sites
Tumour Normal Tumour Normal Tumour Normal Tumour Pa Normal Pa
Total 64 (23/36) 65 (17/26) 47 (17/36) 23 (6/26) 74 (26/35) 46 (12/26) 66 (23/36) 38 (10/26)
Sex
Female 12 92 (11/12) 67 (6/9) 67 (8/12) 11 (1/9) 100 (12/12) 44 (4/9) 100 (12/12) 0.002 22 (2/9) 0.39
Male 24 50 (12/24) 63 (10/16) 67 (9/24) 29 (5/17) 56 (15/24) 47 (8/17) 46 (11/24) 47 (8/17)
Age
Mean 65±12.9
Median 68
<68 18 72 (13/18) 60 (9/15) 61 (11/18) 13 (2/15) 88 (15/18) 33 (5/15) 77 (14/18) 0.16 20 (3/15) 0.04
>68 18 10 (10/18) 72 (8/11) 33 (6/18) 36 (4/11) 67 (12/18) 63 (7/11) 50 (9/18) 64 (7/11)
Histology
AC 11 82 (9/11) 40 (4/10) 36 (4/11) 20 (2/10) 91 (10/11) 60 (6/10) 73 (8/11) 0.70b 30 (3/10) 0.67b
SCC 19 58 (11/19) 85 (11/13) 53 (10/19) 23 (3/13) 78 (14/19) 46 (6/13) 63 (12/19) 46 (6/13)
LCC 4 25 (1/4) 0 (0/4) 25 (1/4) 0 (0/1) 25 (1/4) 0 (0/1) 25 (1/4) 0 (0/1)
Other 2 100 (2/2) 100 (2/2) 100 (2/2) 50 (1/2) 100 (2/2) 0 (0/2) 100 (2/2) 50 (1/2)
Stage
I 24 67 (16/24) 68 (13/19) 54 (13/24) 26 (5/19) 83 (19/24) 47 (9/19) 67 (16/24) 0.72 73 (8/19) 0.66
II and III 12 7 (58) 57 (4/7) 33 (4/12) 14 (1/7) 58 (7/12) 43 (3/7) 58 (7/12) 28 (2/7)
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a Fisher exact test.
b Only using AC and SCC, AC: tumours with adenocarcinoma features, SCC: squam
ethylated in 65% (17/26), M5 in 23% (6/26) and M9 in 46% (12/26)
f these samples. Dense methylation was found in 38% (10/26)
f adjacent normal lung tissue samples. When dichotomised into
atients older or younger than the median of 68 years, for the
urpose of creating Table 3, signiﬁcantly more patients with
ense methylation of normal tissue were older than 68 (Table 3).
owever, a t-test of mean ages showed no signiﬁcant difference
etween patients with and without dense methylation of adjacent
ormal lung tissue. When comparing methylation at individual
ites of paired tumour and normal samples using theMcNemar test
Table 4), only the proportion of tumour samples methylated at the
9 site was signiﬁcantly higher than that of corresponding nor-
al samples (p value 0.012). The frequency of dense methylation
as also higher in tumour than in corresponding normal sam-
les (p=0.039). This, however, could mainly be attributed to the
igh frequency of dense methylation in female subjects; all twelve
emales had densely methylated tumour tissue, whereas in only
wo out of nine matched normal tissue samples of female patients,
he corresponding tumour distant normal tissue showed dense
ethylation as well. In male subjects there was no signiﬁcant dif-
erence between dense methylation in tumour and corresponding
able 4
omparison of matched tumour and adjacent normal tissue samples.
Tumour Normal
U M Total Pa
M1
U 3 4 7
M 6 13 19 0.75
Total 9 17 26
M5
U 13 1 14
M 7 5 12 0.07
Total 20 6 26
M9
U 4 1 5
M 10 11 21 0.012
Total 14 12 26
Dense
U 6 2 8
M 10 8 18 0.039
Total 16 10 26
: unmethylated, M: methylated.
a 2-Sided McNemar test.ell carcinoma, LCC: large cell carcinoma.
normal tissue. The relation between sex and dense methylation in
tumour samples was conﬁrmed by stepwise binary logistic regres-
sion analysis with forward selection; no other variables (tested
were age, histology and disease stage) were a signiﬁcant improve-
ment of the model.
In six tumour samples, including 4 SCCs and 2 LCCs no methy-
lation was detected at any of the three promoter sites examined,
whereas two of these cases (both SCC) had methylation in tumour
distant normal samples at one and two sites, respectively. No clini-
cal or histopathological characteristics were associated with dense
methylation. There was also no relation between methylation of
individual sites or dense methylation in tumour or normal tissue
specimens anddisease-free survival. Theonly clinical characteristic
associated with disease free survival was disease stage (p=0.036,
data not shown).
As non-lung cancer controls we used normal tissue samples
from patients who underwent surgery for a solitary pulmonary
metastasis of a colon carcinoma (n=3) or pulmonary lesions that
turned out to be ﬁbrous scar tissue (n=3). Four of these 6 samples
(67%) showed dense methylation as well (Table 2).
4. Discussion
CADM1 silencing is functionally involved in pulmonary car-
cinogenesis [13] and promoter methylation of this gene has been
proposed as a candidate marker for early lung cancer detection [5].
Here, we applied an MSP-based methodology for assessing CADM1
promoter methylation that was previously validated on cervical
material. By determining the methylation status at three differ-
ent regions within the CADM1 promoter, this method predicted
gene silencing in cervical tissue, based on the presence of methyla-
tion at ≥2 regions or dense methylation [23]. We found that dense
methylation was not only frequently present in lung tumour sam-
ples, but also in 38% of corresponding normal samples taken from
the same surgical specimen, as well as four out of six normal lung
samples from patients without primary lung cancer. In the small
subgroup of female patients a clear difference in dense methyla-
tion was observed between tumour and paired normal samples,
warranting further studies.Whereas previous studies limited their analysis to a single
region in the CADM1 promoter, our study included three regions.
Methylation of these regions was heterogeneous; no distinct pat-
tern could be discerned andmethylation frequencies in each region
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ere different. The M9 region was the only single region where
ADM1 methylation was signiﬁcantly more frequent in tumour
amples than in corresponding normal samples. Nevertheless, 12
ut of 26 corresponding normal samples were positive for M9
ethylation. This relatively high frequency of CADM1 promoter
ethylation in tumour adjacent normal specimens could be con-
rmed by application of a newly developed quantitative MSP assay
argeting a region largely overlapping that of M9 to a subset of
ases (n=21). The overall concordance between both assays was
ood (86%) (data not shown). Although for the M5 region the dif-
erence between methylated tumour and normal samples was only
orderline signiﬁcant (p=0.07), it was the region displaying the
ighest speciﬁcity (the least methylation in corresponding normal
amples; 6 out of 26). M5 overlaps the region tested by Fukami
t al. and Kikuchi et al. [15,19], resulting in three CpGs shared
etween the different analyses. Within this region similar methy-
ation frequencies in tumour tissue were found; 47% of primary
SCLCs showed methylation of the M5 region in our study com-
ared with 44% (21/48 and 45/103, respectively) in both other
tudies. No CADM1 methylation in matched normal tissue was
ound in the latter two studies. Other studies on CADM1 methy-
ation in lung specimens have described methylation frequencies
n matched normal lung samples varying from 4% to 7% [20,24].
t is likely that these differences in methylation frequency in nor-
al lung samples reﬂect differences in the sensitivity and targeted
romoter regions between the different assays used. Other studies
ave described varying degrees of cancer-related methylation in
istologically normal lung tissue of lung cancer patients, such as
djacent normal tissue of specimens from lung cancer surgery [25]
nd histologically tumour-free bronchial resection margins [26].
nalogous ﬁndings have been reported in other organs, such as
or MLH1 in colon [27]. These abnormalities are often explained
y the concept of ‘ﬁeld cancerization’, i.e. (epi)genetically affected
umour adjacent areas that represent a premalignant condition
rom which new tumours may emerge. However, given the fact
hat (dense) CADM1 methylation was found in a substantial frac-
ion of normal lung tissue of patients of a similar age who did
ot suffer from lung cancer, ﬁeld cancerization is unlikely to be
he only explanation for the observed methylation background
n normal lung tissue. Instead, methylation observed in normal
ung tissue may be the result of environmental insult, aging, or
eﬂect some degree of physiological, epigenetic regulation of the
ADM1 gene in certain cell types present in lung tissue speci-
ens.
Strikingly, all female patients had dense CADM1 methylation
f tumour samples compared with only 46% of male patients. This
nding is contrary to the ﬁndings of Kikuchi et al. [19], who found
igniﬁcantly more male patients with tumour CADM1 promoter
ethylation. However, they found a relation with smoking index
s well. Since we have no information about the patients’ smoking
istory it could not be included in our analysis, and it is therefore
ncertain whether different smoking habits could explain the dis-
repancy between our results and those of Kikuchi et al. Although
his seems irrelevant for our main conclusion, the lack of speciﬁcity
f CADM1 methylation testing, no ﬁrm conclusions can be drawn
n the potential biomarker value of CADM1 promoter methylation
n non-smokers. Moreover, we could not reproduce the relation
etween prognosis and CADM1 expression in adenocarcinomas
ound in the same study [19].
. ConclusionPresent study shows that methylation of different sites of
he CADM1 promoter is not only common in NSCLC, but can
lso frequently be detected in normal lung tissue of both lung
[ancer 72 (2011) 316–321
cancer patients and patients without lung cancer. These data
indicate that CADM1 methylation analysis has insufﬁcient speci-
ﬁcity to be included in a panel of markers for early lung cancer
detection in an unselected population. We also did not ﬁnd
any evidence for CADM1 methylation analysis being a candidate
prognostic marker for patients with lung cancer. Nevertheless, a
diagnostic value for selected subjects, such as females, cannot be
excluded.
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